[{"orgOrder":0,"company":"AcuraStem","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AS-202","moa":"PIKfyve","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"AcuraStem \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AcuraStem","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Funding","leadProduct":"AS-202","moa":"PIKfyve","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"AcuraStem \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ US Department of Defense"}]

Find Clinical Drug Pipeline Developments & Deals by AcuraStem

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Under the terms of the agreement, Takeda will receive an exclusive, worldwide license to AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

                          Product Name : AS-202

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          September 25, 2023

                          Lead Product(s) : AS-202

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : $580.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The CDMRP award nomination underscores the significance of AcuraStem’s drug candidate AS-202. AcuraStem’s most advanced therapeutic candidate, AS-202, lowers levels of the lipid kinase PIKFYVE.

                          Product Name : AS-202

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          May 25, 2021

                          Lead Product(s) : AS-202

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : US Department of Defense

                          Deal Size : $1.0 million

                          Deal Type : Funding

                          blank